Brief: Astrazeneca Pharma India Receives Permission To Import Pharmaceutical Formulations For Dapagliflozin
24/07/2023 13:47
July 24 (Reuters) - Astrazeneca Pharma India Ltd
ASTR.NS :
* RECEIVED PERMISSION TO IMPORT PHARMACEUTICAL FORMULATIONS
OF NEW
DRUG
* PERMISSION FROM DRUGS CONTROLLER GENERAL OF INDIA FOR
DAPAGLIFLOZIN TABLETS 10 MG
* PERMISSION PAVES WAY FOR LAUNCH OF DAPAGLIFLOZIN TABLETS
10MG IN
INDIA
Source text for Eikon: ID:nBSE3Dl1D8
Further company coverage: ASTR.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan
India's Astrazeneca Pharma logs worst slide in two months on quarterly profit drop
Brief: Astrazeneca Pharma India March-Quarter PAT 448.8 Million Rupees
Brief: Astrazeneca Pharma India Recommends Dividend Of 36 Rupees Per Equity Share For Fy2025-26
Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication